HARROW, INC. 4

Chief Scientific Officer Amir Shojaei exercised options for 11,250 Harrow, Inc. shares at $35.96 and sold all 11,250 shares at $40.00 in a same‑day sale to fund the exercise and costs, leaving 11,250 shares owned afterward.

On August 14, 2026, Harrow, Inc. Chief Scientific Officer Amir Shojaei exercised stock options for 11,250 shares of common stock at an exercise price of $35.96 per share and simultaneously sold all 11,250 shares in a broker-assisted same‑day sale at $40.00 per share to cover the aggregate exercise price and related transaction costs, resulting in no net increase in his common stock holdings, which stood at 11,250 shares after the transactions. The underlying stock option, granted on January 6, 2025 and exercisable until January 6, 2035, vests 25% at the one‑year anniversary of grant with the remainder vesting in 12 equal quarterly installments through January 6, 2029. These transactions reflect routine option exercise and sell‑to‑cover activity rather than a discretionary open‑market purchase or sale of already‑held shares.

Filing Facts

CIK

1360214

Ticker

HROW

Form

4

Source Type

fda

Accession

0001493152-26-038807

Alert Tier

5